Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …

Background Neoadjuvant immunotherapy has been demonstrated to be effective and safe in
resectable non-small cell lung cancer (NSCLC) patients. However, the presence of different …

Background Studying the application of neoadjuvant immunochemotherapy (NICT) in the
real world and evaluating its effectiveness and safety in comparison with neoadjuvant …

Objectives Early stage non-small cell lung cancer (NSCLC) patients who undergo complete
resection continue to demonstrate high risk of recurrence and death. The advent of the …

Introduction Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
Despite this, evidence supporting optimal management of certain stages remains a topic of …

Background Programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
displayed considerable advantages in neoadjuvant therapy of non-small cell lung cancer …

Background Preoperative immunotherapy has shed light on the management of resectable
non-small cell lung cancer (NSCLC). However, whether neoadjuvant immunotherapy …

Background This open, observational clinical study aimed to investigate the efficacy, safety
and survival outcomes of neoadjuvant chemotherapy, neoadjuvant immunotherapy with …

Background The impact of neoadjuvant chemoimmunotherapy on pulmonary resection and
related outcomes had been poorly reported in previous studies. The present study aims to …

Background In recent years, neoadjuvant immunotherapy combined with chemotherapy has
been used to treat locally advanced non-small cell lung cancer (NSCLC); however, no data …